Targeting specific cancer cell pathways can improve the efficacy and specificity of cancer treatments. For instance, drugs like vemurafenib target the BRAFV600E mutation in the MAPK/ERK pathway, providing significant benefits to melanoma patients. Similarly, inhibitors of the PI3K/AKT/mTOR pathway, like everolimus, have shown promise in treating various cancers.
